M&A / Deals Otsuka grows in neuroplastogens with $1.225bn Transcend buy PharmaphorumOtsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.M&A / DealsNeuroscienceRead full story pharminent March 29, 2026 (Last updated: March 30, 2026) Pharmaphorum Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials. M&A / DealsNeuroscienceRead full story Post navigation Previous: Lilly puts up to $2.75bn into Insilico allianceNext: Trustworthy AI in clinical oversight Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026